Keyvibe-010 fails, but not for the reason you might have expected.

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.

Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

A tumour-agnostic label for Enhertu leads April’s US oncology approvals.

A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.

Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.

The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.